NYMOX PROVIDES UPDATE ON PROSTATIC HYPERPLASIA DRUG TRIAL

Nymox has provided an update on its ongoing multicenter Phase II trial of NX-1207. A recently updated review of overall safety data filed with the FDA has revealed no serious drug side-effects or safety issues thus far. More than 20 clinical sites across the U.S. are involved in the trial to date and patient accrual has proceeded as expected. The pivotal Phase II trial of NX-1207 is expected to be completed later this year.

NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia. In two completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant adverse side-effects or safety problems.

In Phase I and II trials to date, the subjects treated with NX-1207 showed a statistically significant overall mean symptom improvement after one month of 6.87 points and a statistically significant shrinkage in prostate size. There were no significant adverse side-effects from the drug in these trials. Significantly, subjects followed for up to two years post-treatment showed even further statistically significant symptom improvement.